JUBLPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.8
| Stock Code | JUBLPHARMA | Market Cap | 15,714 Cr. | Current Price | 986 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.51 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 1,034 ₹ | DMA 200 | 1,056 ₹ | Chg in FII Hold | -0.60 % |
| Chg in DII Hold | 0.70 % | PAT Qtr | -48.0 Cr. | PAT Prev Qtr | 4.10 Cr. | RSI | 46.6 |
| MACD | -26.8 | Volume | 1,54,176 | Avg Vol 1Wk | 1,16,822 | Low price | 802 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 41.1 % | Qtr Profit Var | -436 % |
| EPS | 1.15 ₹ | Industry PE | 29.2 |
📊 Analysis: JUBLPHARMA is trading at ₹986, below DMA50 (₹1,034) and DMA200 (₹1,056), reflecting short-term weakness. RSI at 46.6 indicates bearish-to-neutral momentum, while MACD negative (-26.8) confirms downward bias. Current volume (1.54L vs avg 1.16L) is slightly higher, showing active participation, but price action remains pressured. The stock is mid-range in its 52-week index (41.1%), offering limited upside intraday.
💡 Optimal Buy Price: ₹980–₹986 (near support zone).
🎯 Profit-Taking Exit Levels: ₹1,000 (first target), ₹1,020 (second target).
🛡️ Stop-Loss / Loss Protection: ₹965 (below immediate support).
⏱️ If Already Holding: Exit near ₹1,000–₹1,020 if momentum improves. If RSI dips below 45 or price fails to hold ₹980 with weakening volume, consider exiting closer to ₹965 to protect capital.
Positive
- Dividend yield of 0.51% adds investor confidence.
- Book value (₹141) provides margin of safety relative to current price.
- DII holding increased (+0.70%), showing domestic institutional support.
- Debt-to-equity ratio of 0.02 indicates negligible leverage risk.
Limitation
- Stock trading below DMA50 and DMA200 shows weak technical trend.
- ROCE (2.91%) and ROE (1.04%) are very weak compared to peers.
- EPS at ₹1.15 is modest relative to valuation.
- Absence of meaningful PEG ratio limits growth visibility.
Company Negative News
- Quarterly PAT turned negative (-₹48 Cr.) compared to ₹4.1 Cr. previously.
- Quarterly profit variation (-436%) highlights severe earnings pressure.
- FII holding decreased (-0.60%), reflecting reduced foreign investor confidence.
Company Positive News
- DII stake increased, showing domestic confidence in the company.
- Higher trading volume indicates continued market interest despite weak fundamentals.
Industry
- Pharma sector trades at industry PE of 29.2, but JUBLPHARMA lacks a meaningful P/E due to weak earnings.
- Sector outlook remains stable with demand supported by healthcare needs, though company-specific risks are high.
Conclusion
⚡ JUBLPHARMA is a weak intraday candidate today. Buy near ₹980–₹986 with profit targets at ₹1,000–₹1,020 and stop-loss at ₹965. Momentum indicators suggest limited upside; quick exits are advised if price fails to sustain above support levels.